drugset / Trial / NCT00017251

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

NCT00017251

Phase 1 Completed 12 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may make tumor cells more sensitive to chemotherapy drugs. Phase I trial to study the effectiveness of combination chemotherapy and oblimersen in treating patients who have extensive-stage small cell lung cancer

Timeline

Start
2001-04
Primary completion
2004-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Etoposide Small molecule Intravenous
Subject oblimersen sodium Antisense oligonucleotide Intravenous